SG10201807292YA - Improved reprogramming methods and cell culture platforms - Google Patents

Improved reprogramming methods and cell culture platforms

Info

Publication number
SG10201807292YA
SG10201807292YA SG10201807292YA SG10201807292YA SG10201807292YA SG 10201807292Y A SG10201807292Y A SG 10201807292YA SG 10201807292Y A SG10201807292Y A SG 10201807292YA SG 10201807292Y A SG10201807292Y A SG 10201807292YA SG 10201807292Y A SG10201807292Y A SG 10201807292YA
Authority
SG
Singapore
Prior art keywords
cell culture
culture platforms
reprogramming methods
methods
improved
Prior art date
Application number
SG10201807292YA
Other languages
English (en)
Inventor
Bahram Valamehr
Peter Flynn
Ramzey Abujarour
Megan Robinson
Original Assignee
Fate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fate Therapeutics Inc filed Critical Fate Therapeutics Inc
Publication of SG10201807292YA publication Critical patent/SG10201807292YA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/235—Leukemia inhibitory factor [LIF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/415—Wnt; Frizzeled
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases (EC 2.)
    • C12N2501/724—Glycosyltransferases (EC 2.4.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases (EC 2.)
    • C12N2501/727—Kinases (EC 2.7.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/15043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Transplantation (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
SG10201807292YA 2014-03-04 2015-03-04 Improved reprogramming methods and cell culture platforms SG10201807292YA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461947979P 2014-03-04 2014-03-04

Publications (1)

Publication Number Publication Date
SG10201807292YA true SG10201807292YA (en) 2018-09-27

Family

ID=54055848

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201606934SA SG11201606934SA (en) 2014-03-04 2015-03-04 Improved reprogramming methods and cell culture platforms
SG10201807292YA SG10201807292YA (en) 2014-03-04 2015-03-04 Improved reprogramming methods and cell culture platforms

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG11201606934SA SG11201606934SA (en) 2014-03-04 2015-03-04 Improved reprogramming methods and cell culture platforms

Country Status (11)

Country Link
US (2) US11268069B2 (pt)
EP (3) EP3604499A1 (pt)
JP (5) JP6722108B2 (pt)
KR (4) KR102460549B1 (pt)
CN (1) CN106414721A (pt)
AU (2) AU2015227184B2 (pt)
CA (1) CA2941004A1 (pt)
ES (1) ES2966757T3 (pt)
PT (1) PT3114214T (pt)
SG (2) SG11201606934SA (pt)
WO (1) WO2015134652A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103380212B (zh) 2010-12-22 2017-04-05 菲特治疗公司 用于单细胞分选与增强ipsc重新编程的细胞培养平台
KR102460549B1 (ko) 2014-03-04 2022-10-28 페이트 세러퓨틱스, 인코포레이티드 개선된 재프로그래밍 방법 및 세포 배양 플랫폼
CN107429230B (zh) 2015-01-26 2021-11-12 菲特治疗公司 用于诱导造血细胞分化的方法和组合物
JP2018520688A (ja) 2015-07-21 2018-08-02 ザ チルドレンズ メディカル センター コーポレーション Ｐｄ−ｌ１発現造血幹細胞およびその使用
SG11201802957PA (en) * 2015-10-16 2018-05-30 Fate Therapeutics Inc Platform for the induction & maintenance of ground state pluripotency
JP6979946B2 (ja) * 2015-10-21 2021-12-15 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation ヒト内耳感覚上皮および感覚ニューロンを生成する方法
CA3003152A1 (en) 2015-11-04 2017-05-11 Fate Therapeutics, Inc. Methods and compositions for inducing hematopoietic cell differentiation
CN115806940A (zh) 2015-11-04 2023-03-17 菲特治疗公司 多能细胞的基因组工程改造
US20170226483A1 (en) * 2016-01-12 2017-08-10 Lonza Walkersville, Inc. Methods and Vectors to Produce Vector Free Induced Pluripotent Stem Cells
CN110114470A (zh) * 2016-12-27 2019-08-09 住友化学株式会社 诱导的多能性干细胞的评价方法及选择方法、以及诱导的多能性干细胞的制备方法
CN106754729B (zh) * 2016-12-31 2020-03-17 内蒙古赛科星家畜种业与繁育生物技术研究院有限公司 利用Xist Tale抑制性转录因子制备诱导性多能干细胞的方法
US11879137B2 (en) 2017-09-22 2024-01-23 The Children's Medical Center Corporation Treatment of type 1 diabetes and autoimmune diseases or disorders
AU2018348142A1 (en) * 2017-10-11 2020-04-02 Fate Therapeutics, Inc. Cellular reprogramming using temporal and transient plasmid vector expression system
JP7467339B2 (ja) 2017-12-22 2024-04-15 フェイト セラピューティクス，インコーポレイテッド 強化された免疫エフェクター細胞およびその使用
EP3732286A4 (en) * 2017-12-28 2022-01-05 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone GENERATION OF INDUCED PLURIPOTENT CELLS BY CRISPR ACTIVATION
WO2019180247A1 (en) * 2018-03-22 2019-09-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Method for reprogramming somatic cells
CN109679918A (zh) * 2018-12-25 2019-04-26 合肥中科干细胞再生医学有限公司 一种便捷的人诱导性多能干细胞的制备方法
CN113646424A (zh) * 2019-03-29 2021-11-12 富士胶片株式会社 具有分化成特定细胞的能力的多能干细胞的制造方法及其应用
CN110564673A (zh) * 2019-09-26 2019-12-13 广东工业大学 一种干细胞培养液及其应用
WO2021116362A1 (en) * 2019-12-11 2021-06-17 Repairon Gmbh Expansion of stem cells in suspension in a bioreactor
CA3182863A1 (en) * 2020-06-22 2021-12-30 Life Technologies Corporation Methods and compositions for cultivating pluripotent cell suspensions
AU2021353586A1 (en) * 2020-10-02 2023-05-11 Fate Therapeutics, Inc. Improved reprogramming, maintenance and preservation for induced pluripotent stem cells
US20230302044A1 (en) * 2022-03-28 2023-09-28 Steve Reilly Composition to increase cellularlongevity
WO2024078119A1 (en) * 2022-10-12 2024-04-18 Peking University Methods for chemical reprogramming and pluripotent stem cells

Family Cites Families (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5384253A (en) 1990-12-28 1995-01-24 Dekalb Genetics Corporation Genetic transformation of maize cells by electroporation of cells pretreated with pectin degrading enzymes
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
KR0133372B1 (ko) 1991-09-06 1998-04-23 고야 다다시 4-아미노(알킬)시클로헥산-1-카르복사미드 화합물 및 그 용도
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5702932A (en) 1992-07-20 1997-12-30 University Of Florida Microinjection methods to transform arthropods with exogenous DNA
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
CA2167580A1 (en) 1993-07-22 1995-02-02 Howard Y. Chen Expression of human interleukin-1.beta. in a transgenic animal
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5656610A (en) 1994-06-21 1997-08-12 University Of Southern California Producing a protein in a mammal by injection of a DNA-sequence into the tongue
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
CA2245835A1 (en) 1995-06-14 1997-01-03 The Regents Of The University Of California Novel high affinity human antibodies to tumor antigens
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5780448A (en) 1995-11-07 1998-07-14 Ottawa Civic Hospital Loeb Research DNA-based vaccination of fish
GB9807935D0 (en) 1998-04-14 1998-06-10 Univ Edinburgh Lineage specific cells and progenitor cells
US5945100A (en) 1996-07-31 1999-08-31 Fbp Corporation Tumor delivery vehicles
CZ301044B6 (cs) 1996-08-12 2009-10-21 Mitsubishi Tanabe Pharma Léciva obsahující amidové deriváty inhibující Rho kinázu
US5981274A (en) 1996-09-18 1999-11-09 Tyrrell; D. Lorne J. Recombinant hepatitis virus vectors
JP4327260B2 (ja) 1997-05-07 2009-09-09 フアルマ・マル・エセ・ア Ｌ型カルシウムチャンネルエンハンサーとしてのアプリジン
JP3626206B2 (ja) 1997-06-13 2005-03-02 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Ｓｍａｄ６及びその使用
WO1999001426A1 (en) 1997-07-01 1999-01-14 Warner-Lambert Company 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors
US5994624A (en) 1997-10-20 1999-11-30 Cotton Incorporated In planta method for the production of transgenic plants
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US20060263382A1 (en) 1998-06-20 2006-11-23 Richard Hotchkiss Membrane-permeant peptide complexes for treatment of sepsis
CA2336220A1 (en) 1998-07-24 2000-02-03 The Carnegie Institution Of Washington Method for maintenance and propagation of germline stem cells using members of the tgf-.beta. family of growth factors
GB9819912D0 (en) 1998-09-11 1998-11-04 Univ Edinburgh Propagation and/or derivation of embryonic stem cells
ATE292462T1 (de) 1999-01-07 2005-04-15 Warner Lambert Co Behandlung von asthma anhand von mek-inhibitoren
US6703420B1 (en) 1999-03-19 2004-03-09 Bristol-Myers Squibb Pharma Company Amino-thio-acrylonitriles as MEK inhibitors
AU5250400A (en) 1999-06-18 2001-01-09 Mitsubishi Pharma Corporation Osteogenesis promoters
US6730293B1 (en) 1999-08-24 2004-05-04 Cellgate, Inc. Compositions and methods for treating inflammatory diseases of the skin
WO2001017562A1 (en) 1999-09-02 2001-03-15 Yamanouchi Pharmaceutical Co., Ltd. Osteogenesis promoting agents
US20020142457A1 (en) 1999-12-28 2002-10-03 Akihiro Umezawa Cell having the potentiality of differentiation into cardiomyocytes
US6692736B2 (en) 2000-03-24 2004-02-17 Cell Genesys, Inc. Cell-specific adenovirus vectors comprising an internal ribosome entry site
GEP20053496B (en) 2000-07-19 2005-04-25 Warner Lambert Co Oxygenated Esters of 4-Iodo Phenylamino Benzhydroxamic Acids
PE20021011A1 (es) 2001-03-23 2003-02-01 Bayer Corp Derivados quinazolinicos como inhibidores de la rho-quinasa
ATE353889T1 (de) 2001-03-23 2007-03-15 Bayer Pharmaceuticals Corp Rho-kinase inhibitoren
DE60234824D1 (de) 2001-05-01 2010-02-04 Ca Nat Research Council Induzierbares expressionssystem in eukaryotischen zellen
EP1437403A4 (en) 2001-09-21 2004-10-27 Japan Science & Tech Corp METHOD FOR PATTERNING REPROGRAMMING FACTOR, METHOD OF PATTERNED REPROGRAMMING FACTOR, METHOD FOR USE OF REPROGRAMMING FACTOR, METHOD FOR DIFFERENTIATING AND SIFE-INGENATING FAN
SI1456380T1 (sl) 2001-11-02 2012-11-30 Giuliani Int Ltd Smad inhibitorji za zdravljenje cns bolezni
EP1465900B1 (en) 2002-01-10 2008-05-14 Bayer HealthCare AG Rho-kinase inhibitors
US6943172B2 (en) 2002-01-23 2005-09-13 Bayer Pharmaceuticals Corporation Rho-kinase inhibitors
JP4469179B2 (ja) 2002-01-23 2010-05-26 バイエル ファーマセチカル コーポレーション Ｒｈｏキナーゼ阻害剤としてのピリミジン誘導体
ATE306810T1 (de) 2002-03-05 2005-11-15 Artemis Pharmaceuticals Gmbh Durch inzucht erzeugte von embryonalen stammzellen abgeleitete mäuse
NZ535158A (en) 2002-03-13 2007-06-29 Array Biopharma Inc N3 alkylated benzimidazole derivatives as MEK inhibitors
WO2003082808A1 (fr) 2002-04-03 2003-10-09 Sumitomo Pharmaceuticals Company, Limited. Derives de benzamide
GB0210539D0 (en) 2002-05-08 2002-06-19 Univ Edinburgh Control of es cell self renewal and lineage specification, and medium therefor
EP1562935B1 (de) 2002-10-28 2006-09-06 Bayer HealthCare AG Heteroaryloxy-substituierte phenylaminopyrimidine als rho-kinaseinhibitoren
WO2004045617A1 (en) 2002-11-15 2004-06-03 Warner-Lambert Company Llc Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer
WO2004072068A1 (en) 2003-02-10 2004-08-26 Amgen Inc. Vanilloid receptor ligands and their use in treatments
AU2003901099A0 (en) 2003-03-11 2003-03-27 Es Cell International Pte Ltd. Methods of inducing differentiation of stem cells
US20050075276A1 (en) 2003-03-14 2005-04-07 Christopher Rudd Use of inhibitors of glycogen synthase-3 to augment CD28 dependent -T-cell responses
US20070010008A1 (en) 2005-06-29 2007-01-11 Tissuetech, Inc. Ex vivo expansion of primary animal cells
EP1732581A4 (en) 2003-06-20 2008-06-04 Univ California San Diego POLYPEPTIDE TRANSDUCTION AND FUSOGENIC PEPTIDES
BRPI0414961A (pt) 2003-10-03 2006-11-07 Keiichi Fukuda processo de indução da diferenciação de células tronco em células do miocárdio
CN1863779B (zh) 2003-10-15 2010-05-05 宇部兴产株式会社 吲唑衍生物
CA2542276A1 (en) 2003-10-16 2005-04-28 The University Court Of The University Of Edinburgh Control of es cell self-renewal and lineage specification, and medium therefor
WO2005049812A1 (en) 2003-11-19 2005-06-02 Australian Stem Cell Centre Limited Methods for producing blood products from pluripotent cells in cell culture
WO2005051906A2 (en) 2003-11-19 2005-06-09 Array Biopharma Inc. Heterocyclic inhibitors of mek and methods of use thereof
US20070269412A1 (en) 2003-12-02 2007-11-22 Celavie Biosciences, Llc Pluripotent cells
WO2005074643A2 (en) 2004-01-30 2005-08-18 Smithkline Beecham Corporation Benzamide compounds useful as rock inhibitors
WO2005108416A2 (en) 2004-04-21 2005-11-17 The University Of Chicago Myosin light chain kinase inhibitors and their use
AU2005272681B2 (en) 2004-08-13 2009-11-19 University Of Georgia Research Foundation, Inc. Compositions and methods for self-renewal and differentiation in human embryonic stem cells
US20080268533A1 (en) 2004-08-25 2008-10-30 University Of Georgia Research Foundation, Inc. Methods and Compositions Utilizing Myc and Gsk3Beta to Manipulate the Pluripotency of Embryonic Stem Cells
US20060182724A1 (en) 2005-02-15 2006-08-17 Riordan Neil H Method for expansion of stem cells
US8299076B2 (en) 2005-05-18 2012-10-30 Array Biopharma Inc. Crystalline forms of 2-(2-flouro-4-iodophenylamino)-N-(2-hydroxyethoxy)-1,5-dimethyl-6-oxo-1,6-dihydropyridine-3-carboxamide
AU2006275479B2 (en) 2005-08-01 2012-11-29 Nupotential, Inc. Production of reprogrammed cells with restored potential
US20080242594A1 (en) 2005-09-08 2008-10-02 Mckay Ronald D G Methods for Promoting Stem Cell Proliferation and Survival
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
EP2206724A1 (en) 2005-12-13 2010-07-14 Kyoto University Nuclear reprogramming factor
US20090227032A1 (en) 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
GB0601538D0 (en) 2006-01-26 2006-03-08 Univ Birmingham Epigenetic analysis
EP1992360A4 (en) 2006-02-01 2010-02-17 Univ Tokyo USE IN ASSOCIATION OF A TGF-BETA SIGNAL INHIBITOR AND ANTITUMMER AGENT
US7541186B2 (en) 2006-02-22 2009-06-02 University Of Washington Method of generating human retinal progenitors from embryonic stem cells
GB0615327D0 (en) 2006-03-30 2006-09-13 Univ Edinburgh Culture medium containing kinase inhibitors and uses thereof
EP2457995A1 (en) 2006-03-30 2012-05-30 The University Court of The University of Edinburgh Culture medium containing kinase inhibitors, and uses thereof
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
AU2007248609B2 (en) 2006-05-02 2012-11-01 Wisconsin Alumni Research Foundation Method of differentiating stem cells into cells of the endoderm and pancreatic lineage
CA2656398A1 (en) 2006-06-30 2008-01-10 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
US7989458B2 (en) 2006-07-14 2011-08-02 Novartis Ag Pyrimidine derivatives as alk-5 inhibitors
US20080020014A1 (en) 2006-07-19 2008-01-24 Paul Consigny Implantable devices containing nuclear receptor ligands for the treatment of vascular and related disorders
ZA200901914B (en) 2006-09-22 2010-06-30 Riken Stem cell culture medium and method
JP2008099662A (ja) 2006-09-22 2008-05-01 Institute Of Physical & Chemical Research 幹細胞の培養方法
GB0622395D0 (en) 2006-11-09 2006-12-20 Univ Cambridge Tech Methods relating to pluripotent cells
WO2008089351A1 (en) 2007-01-17 2008-07-24 Wisconsin Alumni Research Foundation Improved culture of stem cells
US20100172883A1 (en) 2007-01-19 2010-07-08 Bruneau Benoit Gaetan Methods of generating cardiomyocytes
US9175260B2 (en) 2007-01-30 2015-11-03 TheUniversity of Georgia Research Foundation, Inc. Early mesoderm cells, a stable population of mesendoderm cells that has utility for generation of endoderm and mesoderm lineages and multipotent migratory cells (MMC)
WO2008105630A1 (en) 2007-02-27 2008-09-04 Procell Therapeutics Inc. Combined use of cell permeable nanog and oct4 for increasing self-renewal and suppressing differentiation of stem cells
ES2703592T3 (es) 2007-03-07 2019-03-11 Mei Pharma Inc Combinación de agente anticancerígeno de bencimidazol y un segundo agente anticancerígeno
WO2008126932A2 (en) 2007-04-09 2008-10-23 Riken Epigenetical regulation of brain plasticity
EP2886646B1 (en) 2007-04-18 2019-08-14 Hadasit Medical Research Services & Development Limited Stem cell-derived retinal pigment epithelial cells
US7878210B2 (en) 2007-06-04 2011-02-01 Philip Morris Usa Inc. Cellulose acetate fiber modification
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
US9213999B2 (en) 2007-06-15 2015-12-15 Kyoto University Providing iPSCs to a customer
DK2173863T3 (en) 2007-06-29 2019-01-21 Fujifilm Cellular Dynamics Inc Automated method and apparatus for embryonic stem cell culture
US20120282229A1 (en) 2007-08-01 2012-11-08 Christian Kannemeier Non-viral delivery of transcription factors that reprogram human somatic cells into a stem cell-like state
ES2589122T3 (es) 2007-08-31 2016-11-10 Whitehead Institute For Biomedical Research Estimulación de la ruta de la Wnt en la reprogramación de células somáticas
WO2009057831A1 (ja) 2007-10-31 2009-05-07 Kyoto University 核初期化方法
US20110151447A1 (en) 2007-11-06 2011-06-23 Children's Medical Center Corporation Method to produce induced pluripotent stem (ips) cells from non-embryonic human cells
JP4604076B2 (ja) 2007-11-07 2010-12-22 国立大学法人静岡大学 燃料電池用電解質膜
WO2009073523A2 (en) 2007-11-29 2009-06-11 Children's Hospital Of Orange County De-differentiation of human cells
US20110190729A1 (en) 2007-11-30 2011-08-04 Cytomatrix Pty Ltd Methods of inducing pluripotency involving sox2 protein
AU2008329563A1 (en) 2007-11-30 2009-06-04 Cytomatrix Pty Ltd Methods of inducing pluripotency involving Oct4 protein
AU2009225665B9 (en) 2008-03-17 2015-01-15 The Scripps Research Institute Combined chemical and genetic approaches for generation of induced pluripotent stem cells
JP2011516042A (ja) 2008-03-17 2011-05-26 へルムホルツ・ツェントルム・ミュンヘン−ドイチェス・フォルシュングスツェントルム・ヒューア・ゲズントハイト・ウント・ウムヴェルト（ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング） 部位特異的組み換えを用いて無ベクター誘導多能性幹（ｉＰＳ）細胞を作製するベクターおよびその方法
CN101550406B (zh) 2008-04-03 2016-02-10 北京大学 制备多潜能干细胞的方法,试剂盒及用途
JP5562231B2 (ja) * 2008-07-30 2014-07-30 国立大学法人京都大学 効率的な人工多能性幹細胞の樹立方法
US8298825B1 (en) 2008-08-25 2012-10-30 The General Hospital Corporation TGF-beta receptor inhibitors to enhance direct reprogramming
NZ592622A (en) 2008-11-04 2012-10-26 Viacyte Inc Stem cell aggregate suspension compositions and methods for differentiation thereof
CN105001196B (zh) 2008-12-03 2017-05-10 斯克里普斯研究所 干细胞培养
CN102317442B (zh) 2008-12-17 2014-08-13 斯克里普斯研究所 干细胞的产生和保持
US20120122212A1 (en) 2009-03-06 2012-05-17 Marica Grskovic Tgf-beta pathway inhibitors for enhancement of cellular reprogramming of human cells
US8609417B2 (en) 2009-04-13 2013-12-17 The Regents Of The University Of California Methods and compositions for stem cell cultures
AU2010253844A1 (en) 2009-05-27 2012-02-02 Center Of Regenerative Medicine Of Barcelona, Spain Generation of genetically corrected disease-free induced pluripotent stem cells
WO2010137348A1 (en) 2009-05-29 2010-12-02 Keio University Method for selecting clone of induced pluripotent stem cells
US8524498B2 (en) 2009-05-29 2013-09-03 The General Hospital Corporation Methods and compositions for homologous recombination in human cells
KR101772860B1 (ko) * 2009-06-05 2017-08-30 셀룰러 다이내믹스 인터내셔널, 인코포레이티드 Ｔ 세포 및 조혈 세포의 재프로그래밍
WO2011016588A1 (en) 2009-08-07 2011-02-10 Kyoto University Method of efficiently establishing induced pluripotent stem cells
WO2011047300A1 (en) 2009-10-16 2011-04-21 The Scripps Research Institute Induction of pluripotent cells
KR101874463B1 (ko) 2009-10-31 2018-08-02 뉴 월드 레보러토리즈 인코포레이티드. 세포의 재프로그램화 방법 및 이의 용도
WO2011056971A2 (en) 2009-11-04 2011-05-12 Cellular Dynamics International, Inc. Episomal reprogramming with chemicals
JP6276918B2 (ja) 2009-11-12 2018-02-07 テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド 多能性幹細胞を未分化状態で培養する培地、細胞培養および方法
JP5827220B2 (ja) * 2010-01-22 2015-12-02 国立大学法人京都大学 人工多能性幹細胞の樹立効率改善方法
WO2011103343A2 (en) 2010-02-17 2011-08-25 Biotime Inc. Methods for telomere length and genomic dna quality control analysis in pluripotent stem cells
US8486701B2 (en) 2010-03-05 2013-07-16 University Of Houston ETS2 and MESP1 generate cardiac progenitors from fibroblasts
AU2011235212B2 (en) 2010-03-31 2014-07-31 The Scripps Research Institute Reprogramming cells
US20110306516A1 (en) 2010-06-15 2011-12-15 The New York Stem Cell Foundation Methods for producing induced pluripotent stem cells
DK2582794T3 (en) 2010-06-15 2018-05-22 Cellular Dynamics Int Inc GENERATION OF INDUCED PLURIPOTENT STEM CELLS FROM SMALL VOLUMES OF PERIPHERAL BLOOD
WO2011158852A1 (ja) 2010-06-15 2011-12-22 国立大学法人東京大学 誘導型多能性幹細胞の製造方法
US8765470B2 (en) 2010-08-04 2014-07-01 Cellular Dynamics International, Inc. Reprogramming immortalized B-cells to induced pluripotent stem cells
CN103380212B (zh) * 2010-12-22 2017-04-05 菲特治疗公司 用于单细胞分选与增强ipsc重新编程的细胞培养平台
US9458131B2 (en) * 2011-11-08 2016-10-04 Emory University Compounds and compositions used to epigenetically transform cells and methods related thereto
US9834755B2 (en) 2011-12-08 2017-12-05 Fred Hutchinson Cancer Research Center Compositions and methods for enhanced generation of hematopoietic stem/progenitor cells
WO2013159103A1 (en) * 2012-04-20 2013-10-24 Whitehead Institute For Biomedical Research Programming and reprogramming of cells
JP6164746B2 (ja) 2012-05-22 2017-07-19 国立大学法人 東京大学 抗原特異的ｔ細胞の製造方法
US9166832B1 (en) 2013-10-04 2015-10-20 Altera Corporation Methods and apparatus for decision feedback equalization adaptation
KR102460549B1 (ko) 2014-03-04 2022-10-28 페이트 세러퓨틱스, 인코포레이티드 개선된 재프로그래밍 방법 및 세포 배양 플랫폼
SG11201802957PA (en) 2015-10-16 2018-05-30 Fate Therapeutics Inc Platform for the induction & maintenance of ground state pluripotency
CN115806940A (zh) 2015-11-04 2023-03-17 菲特治疗公司 多能细胞的基因组工程改造

Also Published As

Publication number Publication date
JP2021000107A (ja) 2021-01-07
EP3114214B1 (en) 2023-11-01
AU2015227184B2 (en) 2021-05-20
US20220228125A1 (en) 2022-07-21
SG11201606934SA (en) 2016-09-29
US20170073643A1 (en) 2017-03-16
EP3114214A4 (en) 2017-08-09
US11268069B2 (en) 2022-03-08
JP2017506904A (ja) 2017-03-16
JP2022082668A (ja) 2022-06-02
KR20210111884A (ko) 2021-09-13
KR20240091064A (ko) 2024-06-21
EP3114214A1 (en) 2017-01-11
JP2019187454A (ja) 2019-10-31
KR102670874B1 (ko) 2024-05-31
AU2015227184A1 (en) 2016-09-15
WO2015134652A1 (en) 2015-09-11
EP3805369A1 (en) 2021-04-14
ES2966757T3 (es) 2024-04-24
AU2021218109B2 (en) 2024-05-02
AU2021218109A1 (en) 2021-09-09
JP7170600B2 (ja) 2022-11-14
KR20220147728A (ko) 2022-11-03
KR102340553B1 (ko) 2021-12-21
JP2023126627A (ja) 2023-09-07
JP6722108B2 (ja) 2020-07-15
CN106414721A (zh) 2017-02-15
CA2941004A1 (en) 2015-09-11
JP2018086018A (ja) 2018-06-07
KR102460549B1 (ko) 2022-10-28
PT3114214T (pt) 2024-01-03
KR20160130260A (ko) 2016-11-10
EP3604499A1 (en) 2020-02-05

Similar Documents

Publication Publication Date Title
SG10201807292YA (en) Improved reprogramming methods and cell culture platforms
SA518391159B1 (ar) مترافقات الألفة- قليلة النيوكليوتيد واستخداماتها
EP3523419A4 (en) COMPOSITIONS AND METHODS FOR PRESERVING CELL VITABILITY
IL255447A0 (en) Optimal solid surfaces, tools to use them and their uses to encourage cell and tissue growth
EP3370741A4 (en) METHODS AND COMPOSITIONS FOR EDITING GENES IN HEMATOPOIETIC STEM CELLS
EP3436570A4 (en) MEDIUM, PROCEDURE, CELLS AND SECRETATED FACTORS FOR STEM CELL CULTURE AND THERAPY
AU2017263716A1 (en) Haematopoietic stem/progenitor cells
CO6561839A2 (es) Alteracion genómica dirigida
EP3070163A4 (en) Method for preparing induced pluripotent stem cell, composition used in method, and uses thereof
EP3161127A4 (en) Cultured mammalian limbal stem cells, methods for generating the same, and uses thereof
EP3194570A4 (en) Methods and compositions for nuclease-mediated genome engineering and correction in hematopoietic stem cells
WO2016027099A3 (en) Resetting pluripotent stem cells
EP3636753A4 (en) PROCESS FOR MANUFACTURING DNA-EDITED EUKARYOTIC CELL AND KIT FOR THIS PROCESS
WO2011056971A3 (en) Episomal reprogramming with chemicals
WO2010033920A3 (en) Compositions and methods for enhancing cell reprogramming
EP2970881A4 (en) Compositions and methods for reprogramming hematopoietic stem cell lineages
MX2016014235A (es) Biosintesis microbiana de ergotioneina.
EP3369810A4 (en) METHOD FOR PRODUCING CELL POPULATION WITH MESENCHYMAL STEM CELLS, MESENCHYMAL STEM CELLS, CELL POPULATION AND PHARMACEUTICAL COMPOSITION
EP3263697A4 (en) Culture medium for culturing mesenchymal stem cell, method for culturing mesenchymal stem cell, and mesenchymal stem cell
EP3284816A4 (en) Culture medium additive, culture medium composition, and method for culturing cells or tissue using same
EP3436035A4 (en) COMPOSITIONS AND METHODS FOR USE OF SMALL MOBILE STEM CELLS
WO2013188469A3 (en) Pathways characterization of cells
EP3412775A4 (en) TRAIL AND DC EXPRESSIVE MESENCHYMIAL STEM CELL AND USE THEREOF
SG11201805846TA (en) Method for producing hepatic stem/precursor cells from mature hepatic cells using low-molecular-weight compound
EP3417061A4 (en) METHOD AND COMPOSITIONS FOR GENETIZING STEM CELLS